ENAGenomicsMUIMedical University of Innsbruck, Department of Gynecology and Obstetricshttps://www.ebi.ac.uk/ena/browser/view/PRJEB93935The identification of novel molecular drivers and the development of new state-of-the-art therapies are critical challenges in ovarian cancer treatment. The present study examined the transcriptomic changes of the dual CDK12/13-inhibitor SR-4835 in platinum-sensitive and platinum-resistant OC cell lines. Ovarian cancer cell lines (A2780, A2780 cis, SK-OV-3, Caov-3, Caov-3 cis) were treated for 24h with 90 nM SR-4835 and transcriptome profiling was performed.ENAfalseSR-4835 in ovarian cancerTranscriptomic changes after CDK12/13 inhibition by SR-4835 in ovarian cancer cell lines2025-07-172025-07-17PRJEB93935